Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2004 Jul;75(7):998–1002. doi: 10.1136/jnnp.2003.021915

Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis

G Davies 1, L Ramio-Torrenta 1, A Hadjiprocopis 1, D Chard 1, C Griffin 1, W Rashid 1, G Barker 1, R Kapoor 1, A Thompson 1, D Miller 1
PMCID: PMC1739100  PMID: 15201359

Abstract

Objectives: To establish whether magnetisation transfer ratio (MTR) histograms are sensitive to change in normal appearing grey matter (NAGM) in early relapsing-remitting multiple sclerosis (RRMS) in the absence of significant disability; and to assess whether grey or white matter MTR measures are associated with clinical measures of impairment in early RRMS

Methods: 38 patients were studied (mean disease duration 1.9 years (range 0.5 to 3.7); median expanded disability status scale (EDSS) 1.5 (0 to 3)), along with 35 healthy controls. MTR was determined from proton density weighted images with and without MT presaturation. SPM99 was used to generate normal appearing white matter (NAWM) and NAGM segments of the MTR map, and partial voxels were minimised with a 10 pu threshold and voxel erosions. Mean MTR was calculated from the tissue segments. Atrophy measures were determined using a 3D fast spoiled gradient recall sequence from 37 patients and 17 controls.

Results: Mean NAGM and NAWM MTR were both reduced in early RRMS (NAGM MTR: 31.9 pu in patients v 32.2 pu in controls; p<0.001; NAWM MTR: 37.9 v 38.3 pu, p = 0.001). Brain parenchymal fraction (BPF) correlated with NAGM MTR, but when BPF was included as a covariate NAGM MTR was still lower in the patients (p = 0.009). EDSS correlated with NAGM MTR (r = 0.446 p = 0.005).

Conclusions: In early RRMS, grey matter MTR abnormality is apparent. The correlation with mild clinical impairment (in this essentially non-disabled cohort) suggests that NAGM MTR could be a clinically relevant surrogate marker in therapeutic trials.

Full Text

The Full Text of this article is available as a PDF (157.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen I. V., McKeown S. R. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci. 1979 Mar;41(1):81–91. doi: 10.1016/0022-510x(79)90142-4. [DOI] [PubMed] [Google Scholar]
  2. Barker G. J., Tofts P. S., Gass A. An interleaved sequence for accurate and reproducible clinical measurement of magnetization transfer ratio. Magn Reson Imaging. 1996;14(4):403–411. doi: 10.1016/0730-725x(96)00019-7. [DOI] [PubMed] [Google Scholar]
  3. Chard D. T., Griffin C. M., McLean M. A., Kapeller P., Kapoor R., Thompson A. J., Miller D. H. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain. 2002 Oct;125(Pt 10):2342–2352. doi: 10.1093/brain/awf240. [DOI] [PubMed] [Google Scholar]
  4. Chard D. T., Griffin C. M., Parker G. J. M., Kapoor R., Thompson A. J., Miller D. H. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain. 2002 Feb;125(Pt 2):327–337. doi: 10.1093/brain/awf025. [DOI] [PubMed] [Google Scholar]
  5. De Stefano N., Matthews P. M., Filippi M., Agosta F., De Luca M., Bartolozzi M. L., Guidi L., Ghezzi A., Montanari E., Cifelli A. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology. 2003 Apr 8;60(7):1157–1162. doi: 10.1212/01.wnl.0000055926.69643.03. [DOI] [PubMed] [Google Scholar]
  6. Dousset V., Grossman R. I., Ramer K. N., Schnall M. D., Young L. H., Gonzalez-Scarano F., Lavi E., Cohen J. A. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology. 1992 Feb;182(2):483–491. doi: 10.1148/radiology.182.2.1732968. [DOI] [PubMed] [Google Scholar]
  7. Evangelou N., Esiri M. M., Smith S., Palace J., Matthews P. M. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol. 2000 Mar;47(3):391–395. [PubMed] [Google Scholar]
  8. Filippi M., Campi A., Dousset V., Baratti C., Martinelli V., Canal N., Scotti G., Comi G. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology. 1995 Mar;45(3 Pt 1):478–482. doi: 10.1212/wnl.45.3.478. [DOI] [PubMed] [Google Scholar]
  9. Fischer J. S., Rudick R. A., Cutter G. R., Reingold S. C. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler. 1999 Aug;5(4):244–250. doi: 10.1177/135245859900500409. [DOI] [PubMed] [Google Scholar]
  10. Gareau P. J., Rutt B. K., Karlik S. J., Mitchell J. R. Magnetization transfer and multicomponent T2 relaxation measurements with histopathologic correlation in an experimental model of MS. J Magn Reson Imaging. 2000 Jun;11(6):586–595. doi: 10.1002/1522-2586(200006)11:6<586::aid-jmri3>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  11. Ge Yulin, Grossman Robert I., Udupa Jayaram K., Babb James S., Mannon Lois J., McGowan Joseph C. Magnetization transfer ratio histogram analysis of normal-appearing gray matter and normal-appearing white matter in multiple sclerosis. J Comput Assist Tomogr. 2002 Jan-Feb;26(1):62–68. doi: 10.1097/00004728-200201000-00009. [DOI] [PubMed] [Google Scholar]
  12. Griffin Colette M., Chard Declan T., Parker Geoff J. M., Barker Gareth J., Thompson Alan J., Miller David H. The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis. J Neurol. 2002 Feb;249(2):193–199. doi: 10.1007/pl00007864. [DOI] [PubMed] [Google Scholar]
  13. Kidd D., Barkhof F., McConnell R., Algra P. R., Allen I. V., Revesz T. Cortical lesions in multiple sclerosis. Brain. 1999 Jan;122(Pt 1):17–26. doi: 10.1093/brain/122.1.17. [DOI] [PubMed] [Google Scholar]
  14. Kuhlmann Tanja, Lingfeld Gueanelle, Bitsch Andreas, Schuchardt Jana, Brück Wolfgang. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain. 2002 Oct;125(Pt 10):2202–2212. doi: 10.1093/brain/awf235. [DOI] [PubMed] [Google Scholar]
  15. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  16. Lublin F. D., Whitaker J. N., Eidelman B. H., Miller A. E., Arnason B. G., Burks J. S. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 1996 Jan;46(1):12–18. doi: 10.1212/wnl.46.1.12. [DOI] [PubMed] [Google Scholar]
  17. McFarland H. F., Barkhof F., Antel J., Miller D. H. The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler. 2002 Feb;8(1):40–51. doi: 10.1191/1352458502ms767xx. [DOI] [PubMed] [Google Scholar]
  18. Molyneux P. D., Barker G. J., Barkhof F., Beckmann K., Dahlke F., Filippi M., Ghazi M., Hahn D., MacManus D., Polman C. Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology. 2001 Dec 26;57(12):2191–2197. doi: 10.1212/wnl.57.12.2191. [DOI] [PubMed] [Google Scholar]
  19. Paolillo A., Pozzilli C., Giugni E., Tomassini V., Gasperini C., Fiorelli M., Mainero C., Horsfield M., Galgani S., Bastianello S. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta. Eur J Neurol. 2002 Nov;9(6):645–655. doi: 10.1046/j.1468-1331.2002.00476.x. [DOI] [PubMed] [Google Scholar]
  20. Peterson J. W., Bö L., Mörk S., Chang A., Trapp B. D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001 Sep;50(3):389–400. doi: 10.1002/ana.1123. [DOI] [PubMed] [Google Scholar]
  21. Poser C. M., Paty D. W., Scheinberg L., McDonald W. I., Davis F. A., Ebers G. C., Johnson K. P., Sibley W. A., Silberberg D. H., Tourtellotte W. W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
  22. Sailer M., O'Riordan J. I., Thompson A. J., Kingsley D. P., MacManus D. G., McDonald W. I., Miller D. H. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology. 1999 Feb;52(3):599–606. doi: 10.1212/wnl.52.3.599. [DOI] [PubMed] [Google Scholar]
  23. Traboulsee A., Dehmeshki J., Brex P. A., Dalton C. M., Chard D., Barker G. J., Plant G. T., Miller D. H. Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS. Neurology. 2002 Jul 9;59(1):126–128. doi: 10.1212/wnl.59.1.126. [DOI] [PubMed] [Google Scholar]
  24. Trapp B. D., Peterson J., Ransohoff R. M., Rudick R., Mörk S., Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 Jan 29;338(5):278–285. doi: 10.1056/NEJM199801293380502. [DOI] [PubMed] [Google Scholar]
  25. van Waesberghe J. H., Kamphorst W., De Groot C. J., van Walderveen M. A., Castelijns J. A., Ravid R., Lycklama à Nijeholt G. J., van der Valk P., Polman C. H., Thompson A. J. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol. 1999 Nov;46(5):747–754. doi: 10.1002/1531-8249(199911)46:5<747::aid-ana10>3.3.co;2-w. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES